SEC Tracker
Get the app

Heron Therapeutics HRTX

Mark Earl Hensley (COO) received 11,770 HRTX in vested stock units

Form
4
Filed
Importance
Routine
  1. Oct 30, 2026 - Acquired 11,770 shares
  2. Owned 179,322 shares after transaction

Written from the Form 4 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Heron Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  2. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  3. Annexon ANNX public float $244M, Jun 30, 2025
  4. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  5. DBV Technologies DBVT public float $251M, Jun 30, 2025